Financhill
Buy
74

SLNO Quote, Financials, Valuation and Earnings

Last price:
$75.22
Seasonality move :
-5.35%
Day range:
$74.74 - $76.16
52-week range:
$36.93 - $76.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3,861.48x
P/B ratio:
14.07x
Volume:
424.1K
Avg. volume:
2M
1-year change:
52.81%
Market cap:
$3.4B
Revenue:
--
EPS (TTM):
-$4.26

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
SLNO
Soleno Therapeutics
$11.6M -- -- -- $108.63
ALNY
Alnylam Pharmaceuticals
$730M $0.50 -5.4% -34.62% $320.56
AXSM
Axsome Therapeutics
$165.1M -$0.67 61.86% -6.01% $177.12
BBIO
BridgeBio Pharma
$85.7M -$0.61 4376.62% -18.53% $57.72
LEGN
Legend Biotech
$277.4M -$0.18 104.21% -8.33% $77.99
MDGL
Madrigal Pharmaceuticals
$181.2M -$3.48 956.32% -50.21% $421.93
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
SLNO
Soleno Therapeutics
$75.23 $108.63 $3.4B -- $0.00 0% 3,861.48x
ALNY
Alnylam Pharmaceuticals
$259.39 $320.56 $33.6B -- $0.00 0% 14.20x
AXSM
Axsome Therapeutics
$112.21 $177.12 $5.5B -- $0.00 0% 13.94x
BBIO
BridgeBio Pharma
$38.57 $57.72 $7.3B -- $0.00 0% 57.19x
LEGN
Legend Biotech
$33.17 $77.99 $6.1B -- $0.00 0% 9.67x
MDGL
Madrigal Pharmaceuticals
$315.48 $421.93 $7B -- $0.00 0% 21.66x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
SLNO
Soleno Therapeutics
-- -2.484 -- --
ALNY
Alnylam Pharmaceuticals
89.88% 1.597 2.93% 2.84x
AXSM
Axsome Therapeutics
76.02% 1.593 4.39% 1.99x
BBIO
BridgeBio Pharma
925.32% 1.067 28.12% 4.31x
LEGN
Legend Biotech
22.45% 0.912 5.04% 4.49x
MDGL
Madrigal Pharmaceuticals
14.24% 1.767 1.61% 5.41x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
SLNO
Soleno Therapeutics
-- -$58.8M -- -- -- -$24M
ALNY
Alnylam Pharmaceuticals
$523.1M $18.1M -26.39% -- -0.5% -$127.3M
AXSM
Axsome Therapeutics
$108.3M -$61.6M -96.73% -244.32% -61.14% -$26.2M
BBIO
BridgeBio Pharma
$114M -$103.8M -145.93% -- -109.29% -$200.8M
LEGN
Legend Biotech
$112.6M -$74.4M -12.31% -15.44% 24.48% -$84.5M
MDGL
Madrigal Pharmaceuticals
$132.7M -$79.3M -43.17% -49.57% -50.96% -$88.9M

Soleno Therapeutics vs. Competitors

  • Which has Higher Returns SLNO or ALNY?

    Alnylam Pharmaceuticals has a net margin of -- compared to Soleno Therapeutics's net margin of -9.67%. Soleno Therapeutics's return on equity of -- beat Alnylam Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    ALNY
    Alnylam Pharmaceuticals
    88.04% -$0.44 $1.1B
  • What do Analysts Say About SLNO or ALNY?

    Soleno Therapeutics has a consensus price target of $108.63, signalling upside risk potential of 44.39%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $320.56 which suggests that it could grow by 23.58%. Given that Soleno Therapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe Soleno Therapeutics is more attractive than Alnylam Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    ALNY
    Alnylam Pharmaceuticals
    12 8 1
  • Is SLNO or ALNY More Risky?

    Soleno Therapeutics has a beta of -2.668, which suggesting that the stock is 366.818% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.169, suggesting its less volatile than the S&P 500 by 83.104%.

  • Which is a Better Dividend Stock SLNO or ALNY?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or ALNY?

    Soleno Therapeutics quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Soleno Therapeutics's net income of -$56M is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,861.48x versus 14.20x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    3,861.48x -- -- -$56M
    ALNY
    Alnylam Pharmaceuticals
    14.20x -- $594.2M -$57.5M
  • Which has Higher Returns SLNO or AXSM?

    Axsome Therapeutics has a net margin of -- compared to Soleno Therapeutics's net margin of -63.08%. Soleno Therapeutics's return on equity of -- beat Axsome Therapeutics's return on equity of -244.32%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    AXSM
    Axsome Therapeutics
    91.15% -$1.54 $237.7M
  • What do Analysts Say About SLNO or AXSM?

    Soleno Therapeutics has a consensus price target of $108.63, signalling upside risk potential of 44.39%. On the other hand Axsome Therapeutics has an analysts' consensus of $177.12 which suggests that it could grow by 57.53%. Given that Axsome Therapeutics has higher upside potential than Soleno Therapeutics, analysts believe Axsome Therapeutics is more attractive than Soleno Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    AXSM
    Axsome Therapeutics
    13 0 0
  • Is SLNO or AXSM More Risky?

    Soleno Therapeutics has a beta of -2.668, which suggesting that the stock is 366.818% less volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.356%.

  • Which is a Better Dividend Stock SLNO or AXSM?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or AXSM?

    Soleno Therapeutics quarterly revenues are --, which are smaller than Axsome Therapeutics quarterly revenues of $118.8M. Soleno Therapeutics's net income of -$56M is higher than Axsome Therapeutics's net income of -$74.9M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,861.48x versus 13.94x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    3,861.48x -- -- -$56M
    AXSM
    Axsome Therapeutics
    13.94x -- $118.8M -$74.9M
  • Which has Higher Returns SLNO or BBIO?

    BridgeBio Pharma has a net margin of -- compared to Soleno Therapeutics's net margin of -143.55%. Soleno Therapeutics's return on equity of -- beat BridgeBio Pharma's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    BBIO
    BridgeBio Pharma
    97.74% -$0.88 $209.5M
  • What do Analysts Say About SLNO or BBIO?

    Soleno Therapeutics has a consensus price target of $108.63, signalling upside risk potential of 44.39%. On the other hand BridgeBio Pharma has an analysts' consensus of $57.72 which suggests that it could grow by 49.66%. Given that BridgeBio Pharma has higher upside potential than Soleno Therapeutics, analysts believe BridgeBio Pharma is more attractive than Soleno Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    BBIO
    BridgeBio Pharma
    10 3 0
  • Is SLNO or BBIO More Risky?

    Soleno Therapeutics has a beta of -2.668, which suggesting that the stock is 366.818% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.149, suggesting its more volatile than the S&P 500 by 14.912%.

  • Which is a Better Dividend Stock SLNO or BBIO?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or BBIO?

    Soleno Therapeutics quarterly revenues are --, which are smaller than BridgeBio Pharma quarterly revenues of $116.6M. Soleno Therapeutics's net income of -$56M is higher than BridgeBio Pharma's net income of -$167.4M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,861.48x versus 57.19x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    3,861.48x -- -- -$56M
    BBIO
    BridgeBio Pharma
    57.19x -- $116.6M -$167.4M
  • Which has Higher Returns SLNO or LEGN?

    Legend Biotech has a net margin of -- compared to Soleno Therapeutics's net margin of 14.09%. Soleno Therapeutics's return on equity of -- beat Legend Biotech's return on equity of -15.44%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    LEGN
    Legend Biotech
    60.37% $0.14 $1.3B
  • What do Analysts Say About SLNO or LEGN?

    Soleno Therapeutics has a consensus price target of $108.63, signalling upside risk potential of 44.39%. On the other hand Legend Biotech has an analysts' consensus of $77.99 which suggests that it could grow by 135.13%. Given that Legend Biotech has higher upside potential than Soleno Therapeutics, analysts believe Legend Biotech is more attractive than Soleno Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    LEGN
    Legend Biotech
    11 2 0
  • Is SLNO or LEGN More Risky?

    Soleno Therapeutics has a beta of -2.668, which suggesting that the stock is 366.818% less volatile than S&P 500. In comparison Legend Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock SLNO or LEGN?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Legend Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Legend Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or LEGN?

    Soleno Therapeutics quarterly revenues are --, which are smaller than Legend Biotech quarterly revenues of $186.5M. Soleno Therapeutics's net income of -$56M is lower than Legend Biotech's net income of $26.3M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Legend Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,861.48x versus 9.67x for Legend Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    3,861.48x -- -- -$56M
    LEGN
    Legend Biotech
    9.67x -- $186.5M $26.3M
  • Which has Higher Returns SLNO or MDGL?

    Madrigal Pharmaceuticals has a net margin of -- compared to Soleno Therapeutics's net margin of -53.36%. Soleno Therapeutics's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -49.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    SLNO
    Soleno Therapeutics
    -- -$1.27 --
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
  • What do Analysts Say About SLNO or MDGL?

    Soleno Therapeutics has a consensus price target of $108.63, signalling upside risk potential of 44.39%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $421.93 which suggests that it could grow by 33.74%. Given that Soleno Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Soleno Therapeutics is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    SLNO
    Soleno Therapeutics
    5 0 0
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
  • Is SLNO or MDGL More Risky?

    Soleno Therapeutics has a beta of -2.668, which suggesting that the stock is 366.818% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.906, suggesting its less volatile than the S&P 500 by 190.598%.

  • Which is a Better Dividend Stock SLNO or MDGL?

    Soleno Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Soleno Therapeutics pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios SLNO or MDGL?

    Soleno Therapeutics quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $137.3M. Soleno Therapeutics's net income of -$56M is higher than Madrigal Pharmaceuticals's net income of -$73.2M. Notably, Soleno Therapeutics's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Soleno Therapeutics is 3,861.48x versus 21.66x for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    SLNO
    Soleno Therapeutics
    3,861.48x -- -- -$56M
    MDGL
    Madrigal Pharmaceuticals
    21.66x -- $137.3M -$73.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Did Cathie Wood Buy AMD?
Why Did Cathie Wood Buy AMD?

Noted tech investor Cathie Wood has used the recent stock…

Why Did Salesforce Stock Drop After a Strong Quarter?
Why Did Salesforce Stock Drop After a Strong Quarter?

Popular customer relationship management platform provider Salesforce (NYSE:CRM) has been…

Is Adobe Stock a Bargain With AI Tools Driving Growth?
Is Adobe Stock a Bargain With AI Tools Driving Growth?

The share price of American computer software company Adobe (NASDAQ:ADBE)…

Stock Ideas

Buy
71
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Sell
4
CABO alert for May 3

Cable One [CABO] is down 41.98% over the past day.

Buy
55
PDEX alert for May 3

Pro-Dex [PDEX] is down 32.02% over the past day.

Buy
91
TRUP alert for May 3

Trupanion [TRUP] is up 23.52% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock